Summary.-Doxorubicin in a dose of 60 mg/M2 has been used in the treatment of 23 patients with advanced malignant disease, 18 of whom had carcinoma of the breast. The drug has significant clinical activity on its own, prolonged dosage may be required to obtain a response, and there is a risk of cerebral metastases becoming manifest during treatment which is otherwise successful. Cardiac toxicity appears to be acceptably low with this dose regimen.
THE EFFECTIVENESS of doxorubicin (Adriamycin) as an antitumour agent is now becoming established. The early clinical work from Italy (Bonadonna et al., 1969 ) is expanded and supported by the collated results from the N.C.I. trials reported by Blum and Carter (1973) . Its effectiveness in acute lymphatic leukaemia seems to be similar to that of daunorubicin (Whitehouse et al., 1972) , but it is less effective in acute myeloid leukaemia. The main interest lies in its use in solid tumours.
MATERIALS AND METHODS
A series of 23 patients is presented, 18 with breast carcinoma, one with malignant melanoma, one with reticulum cell sarcoma, one with adamantinoma, one with carcinoma of thyroid gland and one with metastases from an undisclosed primary. In each case doxorubicin was given in a dose of 60 mg/M2 by injection into the tubing of a fast running saline drip. The dose was not repeated in less than 3 weeks because it was thought that more frequent administration might lead to accumulation in tissues with consequent increase in toxicity (Middleman, Luce and Frei, 1971) . Parallel pharmacological studies by Wilkinson and Mawer (1973) have confirmed the slow elimination.
At each visit the patient was assessed for unwanted side-effects. In addition to clinical details which included cardiovascular examination, a full blood count and electrocardiography were carried out. The biochemical profile was checked less frequently.
RESULTS
All of the 18 patients with breast carcinoma had advanced disease and had either failed to respond to, or had relapsed after, conventional therapy using surgery, radiotherapy, hormones and cytotoxic drugs. Only 14 patients had an adequate trial of 3 or more doses of the drug and of these 14 only 2 showed a response consisting of 50%o or more tumour regression which was sustained for at least one month. Five additional patients had a response of less than 5000. In all 7 cases the response was in soft tissue deposits. In one patient a response was not seen until 4 months had elapsed and she then obtained a better than 500% regression which has been maintained for over one year (Table I) .
It is of interest that 2 responders developed cerebral metastases whilst the disease elsewhere remained under control -in one case at 2 months and in the other at 4 months. This is in accord with pharmacological studies (Wilkinson and Mawer, 1973) patients but this could have been due at least in part to progressive malignancy.
Few biochemical abnormalities were noted but the lactic acid dehydrogenase level became raised during treatment in 3 patients.
In view of the known risk of cardiac toxicity this was sought in each patient. The fatal form is a cardiomyopathy characterized by irreversible congestive failure (Gottlieb et al., 1973) 11.5 with other drugs or with radiotherapy. Further, the possibility that the response rate as well as the risk of cardiomyopathy may also increase with prolonged dosage must be kept in mind. Trials are now in progress to assess the drug in combination with established cytotoxic agents in advanced malignant disease.
